Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 6, 2024; 12(34): 6721-6727
Published online Dec 6, 2024. doi: 10.12998/wjcc.v12.i34.6721
Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report
Yu Igata, Masashi Kudo, Motohiro Kojima, Shota Kami, Keishiro Aoki, Tomoyuki Satake, Tatsushi Kobayashi, Motokazu Sugimoto, Shin Kobayashi, Masaru Konishi, Naoto Gotohda
Yu Igata, Masashi Kudo, Shota Kami, Keishiro Aoki, Motokazu Sugimoto, Shin Kobayashi, Masaru Konishi, Naoto Gotohda, Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Motohiro Kojima, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan
Tomoyuki Satake, Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Tatsushi Kobayashi, Department of Diagnostic Radiology, National Cancer Center Hospital East, Chiba 277-8577, Japan
Author contributions: Igata Y, Kami Shota, Aoki K, and Satake T wrote the manuscript; Kudo M, Kojima M, Kobayashi T, Sugimoto M, Kobayashi S, Konishi M and Gotohda N critically revised the manuscript for important intellectual content; Aoki K and Kojima M provided critical pathological guidance; Kobayashi T provided critical radiological guidance; all authors contributed to the acquisition, analysis, interpretation of the data for the work, read and approved the final version of the manuscript to be published.
Informed consent statement: Written informed consent was obtained from the patient for the use of this case report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Masashi Kudo, MD, PhD, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwano-ha, Kashiwa 277-8577, Japan. masakudo@east.ncc.go.jp
Received: May 30, 2024
Revised: September 2, 2024
Accepted: September 9, 2024
Published online: December 6, 2024
Processing time: 134 Days and 22.3 Hours
Core Tip

Core Tip: We report a case of an advanced intrahepatic cholangiocarcinoma (ICC) successfully treated with radical surgery after gemcitabine and cisplatin plus durvalumab. The present case was pathologically classified as a small duct type. This rare case highlights the potential role of conversion surgery in the multimodal treatment strategies for advanced ICC.